drugset / Trial / NCT03906799

Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)

NCT03906799 ↗

Phase 2 Completed 136 enrolled Omeicos Therapeutics GmbH
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, dose-finding, placebo-controlled, parallel group, multicenter, phase II study to evaluate the efficacy, safety, and popPK of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF.

Timeline

Start
2019-03-19
Primary completion
2019-11-20
Completion
2020-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject OMT-28 Small molecule — Oral

Indications